Northway Biotech
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
GA-ASI and USN Test Expanded Sonobuoy Dispensing System For MQ-9B SeaGuardian(R)13.1.2026 19:00:00 CET | Press release
SAN DIEGO, CALIFORNIA / ACCESS Newswire / January 13, 2026 / General Atomics Aeronautical Systems, Inc. (GA-ASI) and the U.S. Navy continue to expand the Anti-Submarine Warfare (ASW) capability of the MQ-9B SeaGuardian® Unmanned Aircraft System (UAS). Flight test was performed on December 17 and featured Sonobuoy Dispensing System (SDS) pods, more than previously tested, doubling the number of sonobuoys available. "Expanding sonobuoy capacity, including Multi-static Active Coherent (MAC) technology for SeaGuardian, has been an integral part of our advanced ASW strategy to broaden and enhance search areas," said GA-ASI President David R. Alexander. "The wider maritime coverage our MQ-9B's ASW capability provides is extremely valuable to our customers." Sonobuoys are naval sensors that drop from an aircraft into the ocean and help detect submarines. The SeaGuardian deployed AN/SSQ-36 Bathythermal, AN/SSQ-53G Directional Frequency Analysis and Recording (DIFAR) (passive), and AN/SSQ-62F D
Hirth Engines and ePropelled Announce Strategic Collaboration to Advance High-Efficiency Propulsion Systems13.1.2026 15:00:00 CET | Press release
Unifying Strengths to Address a Growing Market COVENTRY, UK / ACCESS Newswire / January 13, 2026 / Hirth Engines, a globally recognized leader in two-stroke engine technology, and ePropelled, an innovator in high-efficiency intelligent electric propulsion and power generation systems , today announced a strategic collaboration aimed at delivering the next generation of hybrid propulsion solutions for the UAV, aerospace, defense, and specialized mobility markets. Driven by increasing demand for reliable, lightweight, and energy-efficient propulsion systems, the partnership brings together Hirth's decades-long expertise in advanced combustion engines with ePropelled's pioneering electric propulsion and power management technologies. Together, the companies will develop integrated hybrid systems designed to offer unmatched performance, extended mission endurance, and greater operational flexibility. Unifying Strengths to Address a Growing Market Under this collaboration, Hirth Engines wil
Polaris Renewable Energy Announces Q4 and Annual 2025 Investor Call Details13.1.2026 15:00:00 CET | Press release
TORONTO, ONTARIO / ACCESS Newswire / January 13, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company") is pleased to announce it will be holding its Earnings Conference Call and Webcast to report its Q4 and annual 2025 Earnings Results on Thursday, February 19th, 2026, at 10:00 am EST. To listen to the call, please dial Toll Free 1 888-506-0062 or International Toll-Free Number 973-528-0011 entry code 743835. or URL: https://www.webcaster4.com/Webcast/Page/2773/51835 A digital recording of the earnings call will be available for replay two hours after the call's completion. Replay Call Information: Toronto: 1 877-481-4010, Passcode: 51835 International (toll-free): 1 919-882-2331, Passcode: 51835 Encore Replay Expiration Date: March 05, 2026 About Polaris Renewable Energy Inc. Polaris Renewable Energy Inc. is a Canadian publicly traded company engaged in the acquisition, development, and operation of renewable energy projects in Latin America and the Caribbean. We
Global Sports Brand U.S. Polo Assn. Announced as Official Jersey and Apparel Sponsor for the Legendary Snow Polo World Cup St. Moritz13.1.2026 13:00:00 CET | Press release
WEST PALM BEACH, FL AND ST. MORITZ, SWITZERLAND / ACCESS Newswire / January 13, 2026 / U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), will make its debut as the Official Jersey and Apparel Sponsor of the 41stSnow Polo World Cup St. Moritz, taking place January 23-25, 2026, on the iconic frozen lake of St. Moritz. U.S. Polo Assn.'s inaugural partnership with the world's most prestigious and legendary snow polo tournament underscores the brand's authentic ties to the game and its continued commitment to supporting polo around the world.Photo Caption: Snow Polo World Cup St. Moritz, with Official Jersey and Apparel Sponsor, U.S. Polo Assn. Photo Credit: Christian Sommer Snow Polo World Cup St. Moritz 2026 is already shaping up to be a record-breaking year, with unprecedented demand for tickets, elite international players, and global attention focused on one of the world's most high-profile polo tournaments played on snow. This event will see more
Clean Air Metals Announces 2026 Strategic Objectives in Historically Strong PGE and Copper Markets13.1.2026 01:10:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / January 12, 2026 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU0(OTCQB:CLRMF) is pleased to provide an overview of its 2026 objectives and highlights of 2025, for its 100%-owned Thunder Bay North ("TBN") Critical Minerals Project in Northwestern Ontario. Critical Project Advancement Objectives Spot prices for platinum, copper and palladium have appreciated by 70% (1000 $/oz), 25% (1.20 $/lb) and 50% 624($/oz) respectively versus study prices, since the results of the Preliminary Economic Assessment (PEA) were announced in the October 9th release. Using the financial model published in the PEA and applying current spot metal prices (as of January 6th), the TBN project shows a $708M1 NPV8 and a pre-tax IRR of 100% (post-tax NPV8 = $494M1 and IRR = 84%).This is a significant improvement in the project outlook in comparison to the PEA results that featured a $219.4M2 pre-tax NPV8 and a pre-tax IRR of 39%. This year, cons
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom